Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 26Lymphoma, Large B-Cell, Diffuse 24Burkitt Lymphoma 19Lymphoma, Follicular 14Lymphoma 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, B-Cell 6Recurrence 5Prostatic Neoplasms, Castration-Resistant 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Biphenotypic, Acute 4Ovarian Neoplasms 3Lymphoproliferative Disorders 3Lymphoma, T-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Prostate Cancer Metastatic 2Plasmablastic Lymphoma 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

niraparib 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-sensitive Prostate Cancer × Prednisone × 90 days × Clear all
NCT04497844 2026-06-05

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡